| Name | Title | Contact Details |
|---|
Ensemble Performing Arts is a partnership of community-focused music and dance businesses that maintain individual identities while sharing resources to ensure their mutual success. We believe that a performing arts education is a lifelong journey and is appropriate for individuals of all ages and skill levels. While many of our teachers are equipped to serve students with collegiate and professional ambitions, and we celebrate our students with these meritorious goals, we are equally delighted to work with students of all abilities seeking to enrich their lives through the performing arts. Students can expect a fun and welcoming learning environment with quality teachers underpinned by individual assessments and personalized guidance throughout their learning journey. While our focus always begins with safe classroom practices and healthy technique, what follows thereafter depends on a students unique interests, abilities, and ambitions. We celebrate differences in both teaching styles and learning styles, and always work to find a good fit for our students among our faculty and programs.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.